Targeted Metabolomics Identifies Pharmacodynamic Biomarkers for BIO 300 Mitigation of Radiation-Induced Lung Injury
- 290 Downloads
Biomarkers serve a number of purposes during drug development including defining the natural history of injury/disease, serving as a secondary endpoint or trigger for intervention, and/or aiding in the selection of an effective dose in humans. BIO 300 is a patent-protected pharmaceutical formulation of nanoparticles of synthetic genistein being developed by Humanetics Corporation. The primary goal of this metabolomic discovery experiment was to identify biomarkers that correlate with radiation-induced lung injury and BIO 300 efficacy for mitigating tissue damage based upon the primary endpoint of survival.
High-throughput targeted metabolomics of lung tissue from male C57L/J mice exposed to 12.5 Gy whole thorax lung irradiation, treated daily with 400 mg/kg BIO 300 for either 2 weeks or 6 weeks starting 24 h post radiation exposure, were assayed at 180 d post-radiation to identify potential biomarkers.
A panel of lung metabolites that are responsive to radiation and able to distinguish an efficacious treatment schedule of BIO 300 from a non-efficacious treatment schedule in terms of 180 d survival were identified.
These metabolites represent potential biomarkers that could be further validated for use in drug development of BIO 300 and in the translation of dose from animal to human.
KEY WORDSbiomarkers genistein lung injury metabolomics radiation
Acute radiation syndrome
Delayed effects of acute radiation exposure
Federal Drug Administration
False discovery rate
Flow injection analysis
Hematoxylin and eosin
High definition mass spectrometry
High-performance liquid chromatography
Multiple reaction monitoring
Principal component analysis
Partial least squares-discriminate analysis
Polyunsaturated fatty acid
Standard error of the mean
Saturated fatty acid
Total ion chromatogram
Ultra performance liquid chromatography
Extracted ion chromatogram
Whole thorax lung irradiation
- 9.Jackson IL, Zodda A, Gurung G, Pavlovic R, Kaytor MD, Kuskowski MA, Vujaskovic Z. BIO 300, a nanosuspension of Genistein, mitigates pneumonitis/fibrosis following high dose radiation exposure in the C57L/J murine model. Br J Pharmacol 2017. (in review).Google Scholar
- 11.Product development under the animal rule: Guidance for industry. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2015. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm399217.pdf.
- 12.Guidance for industry and FDA staff: Qualification process for drug development tools. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2014. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm230597.pdf.
- 14.Jones JW, Carter CL, Li F, Yu J, Pierzchalski K, Jackson IL, et al. Ultraperformance convergence chromatography-high resolution tandem mass spectrometry for lipid biomarker profiling and identification. Biomed Chromatogr. 2017;31(3):e3822. doi: 10.1002/bmc.3822.
- 18.Biomarkers Used as Outcomes in Development of FDA-Approved Therapeutics (October 2007–December 2015) [10/18/2016]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm483052.htm.
- 22.Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. Curr Protoc Bioinformatics. 2016;55(14.10):1–14.Google Scholar
- 23.Castro-Perez J, Roddy TP, Nibbering NM, Shah V, McLaren DG, Previs S, et al. Localization of fatty acyl and double bond positions in phosphatidylcholines using a dual stage CID fragmentation coupled with ion mobility mass spectrometry. J am Soc Mass Spectrom. 2011;22(9):1552–67.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Pannkuk EL, Fornace AJ Jr, Laiakis EC. Metabolomic applications in radiation biodosimetry: exploring radiation effects through small molecules. Int J Radiat Biol. 2017;12:1–26.Google Scholar
- 35.Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL, et al. Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol. 2005;67(5):1470–84.CrossRefPubMedGoogle Scholar
- 36.Said SI, Berisha HI, Pakbaz H. Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S a. 1996;93(10):4688–92.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.da Cunha AA, Nunes FB, Lunardelli A, Pauli V, Amaral RH, de Oliveira LM, et al. Treatment with N-methyl-D-aspartate receptor antagonist (MK-801) protects against oxidative stress in lipopolysaccharide-induced acute lung injury in the rat. Int Immunopharmacol. 2011;11(6):706–11.CrossRefPubMedGoogle Scholar